This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|October 4, 2021
Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland
Author(s)BioPharm International Editors
Thermo Fisher’s new Swiss facility will initially produce CSL Limited’s recombinant factor IX product Idelvion.
Advertisement
Thermo Fisher Scientific announced that it had opened a new biologics manufacturing site in Lengnau, Switzerland on Oct. 1, 2021. Thermo Fisher assumed operational responsibility of the facility as a result of their strategic partnership with CSL Limited, a biotechnology company, that was announced in 2020.
The Lengnau site is a 1.5 million ft² biologics facility with up to 12,500 L of bioreactor capacity. It joins Thermo Fisher’s biologics manufacturing network that includes Princeton, NJ, St. Louis, MO, Groningen, The Netherlands, Brisbane, Australia, and Hangzhou, China.
Following completion of on-site construction in 2022, the facility will initially manufacture CSL’s next-generation recombinant factor IX product Idelvion for patients with hemophilia B. In addition to this production, Thermo Fisher plans to expand site use to accommodate other biopharma customers in the future.
"We are excited to add the new Lengnau site to our global biologics manufacturing network and we are thrilled to welcome more than 200 new colleagues to Thermo Fisher," said Michel Lagarde, executive vice-president of Thermo Fisher Scientific, in a company press release. "Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers. With the addition of new high-volume stainless-steel capabilities in Lengnau, we are enabling our customers to start their projects with us and stay with us as their manufacturing requirements grow."
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5